|49.33|| +0.18 / +0.37%|
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company operates through two operating divisions: Research and Development and Services. The Research and Development division develops medicines based on novel mode-of-action. The Service division offers target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. The company was founded by Onno van de Stolpe and Rudi Pauwels in 1999 and is headquartered in Mechelen, Belgium.
|Onno van de Stolpe||Chief Executive Officer & Executive Director|
|Bart Filius||Chief Financial Officer|
|Piet Wigerinck||Chief Scientific Officer|
|Andre Hoekema||Senior Vice President-Corporate Development|
|Elizabeth Goodwin||Head-Investor Relations & Corporate Communications|